Articles Tagged With: Pharmacology
-
Dexamethasone for COVID-19 Inpatients Requiring Oxygen
Dexamethasone administration is associated with reduced 28-day mortality in oxygen-requiring COVID-19 patients, including those receiving mechanical ventilation.
-
Study: Few Black Adults Taking Proper Medicine for Difficult-to-Treat Hypertension
Black patients may not receive the right medications or proper lifestyle counseling.
-
Patients Want to Know if Treatment Is No Better than Placebo
Many patients may be surprised to find out the treatment they are taking is not any better than a placebo. Clinicians may think this is no big deal, as long as the person is feeling better and is grateful.
-
Cheap, Common Steroid Shows Efficacy Against COVID-19
British researchers are excited about their discovery, but full results have not been published.
-
Selpercatinib Capsules (Retevmo)
Selpercatinib should be prescribed to treat metastatic rearranged during transfection (RET) fusion-positive, non-small cell lung cancer and advanced or metastatic RET-mutant medullary thyroid cancer.
-
Mother’s Little Helper Swiped from Junior’s Stash?
Adults are abusing ADHD medication for non-medical purposes at an alarming rate. -
Pharmacology Watch: FDA Approves Generic Version of AstraZeneca’s Prilosec
FDA Approves Generic Version of AstraZenecas Prilosec; Pegasys Approved To Treat Hepatitis C; HRT Reduces Alzheimers Risk, Study Says; Heparin Plus Alteplase More Effective; Digoxin Effects Differ By Sex; McClellan Named FDA Commissioner; FDA Actions -
Pharmacology Watch: FDA Approves Generic Version of AstraZeneca’s Prilosec
FDA Approves Generic Version of AstraZenecas Prilosec; Pegasys Approved To Treat Hepatitis C; HRT Reduces Alzheimers Risk, Study Says; Heparin Plus Alteplase More Effective; Digoxin Effects Differ By Sex; McClellan Named FDA Commissioner; FDA Actions -
Pharmacology Watch: High-Dose Rofecoxib Confirmed Prothrombotic, Study Shows
High-Dose Rofecoxib Confirmed Prothrombotic, Study Shows; Losartan Better Than Atenolol for LVH Treatment; Lisinopril, Not Losartan, Improves Myocardial Perfusion; New Fluoroquinolone Study; Warfarin After MI Better Than Aspirin Alone; FDA News -
Pharmacology Watch: High-Dose Rofecoxib Confirmed Prothrombotic, Study Shows
Debate over the cardiovascular effects of COX-2 inhibitors has raged for more than a year since a special communication was published in JAMA last August suggesting an increase in cardiovascular events with rofecoxib (Vioxx). Now a large retrospect, the cohort study from the Tennessee Medicaid program seems to confirm the prothrombotic effects of rofecoxib, at least in high dose.